The impact of HER2-Low expression in salivary duct carcinoma: Clinicopathologic features, survival outcomes, and association with androgen receptor-targeted therapy - Kano, Satoshi; Kawakita, Daisuke; Honma, Yoshitaka; Takahashi, Hideaki; Nakaguro, Masato; Utsumi, Yoshitaka; Saigusa, Natsuki; Hanazawa, Toyoyuki; Tsukahara, Kiyoaki; Okada, Takuro; Okami, Kenji; Yamazaki, Keisuke; et al. (Oral oncology, 2025)
Keywords: Adult; Aged; Aged, 80 and over; Androgen receptor; Combined androgen blockade; Female; Head and neck cancer; Hematology, Oncology, and Palliative Medicine; HER2; HER2-low; Humans; Male; Middle Aged; Molecular Targeted Therapy; Otolaryngology; Prognosis; Receptor, ErbB-2 - metabolism; Receptors, Androgen - metabolism; Salivary duct carcinoma; Salivary Ducts - pathology; Salivary gland cancer; Salivary Gland Neoplasms - drug therapy; Salivary Gland Neoplasms - metabolism; Salivary Gland Neoplasms - mortality; Salivary Gland Neoplasms - pathology; BC; HER2-low; PR; IHC; DTX; HR; ORR; SD; CBR; SDC; PFS; Tmab; RFS; ISH; T-DXd; OS; CAB; CI; Salivary duct carcinoma; Combined androgen blockade; EN; EP; SGC; CR; AR; PD; Salivary gland cancer; Androgen receptor; NE; Head and neck cancer; CXPA; HER2; salivary gland carcinoma; extreme negative; stable disease; relapse-free survival; overall survival; carcinoma ex pleomorphic adenoma; extreme positive; hormone receptor; objective response rate; clinical benefit rate; in situ hybridization; progressive disease; trastuzumab deruxtecan; docetaxel; immunohistochemistry; partial response; non-extreme; progression-free survival; breast cancer; complete response; human epidermal growth factor receptor 2; trastuzumab; hazard ratio; confidence interval